Author:
Szucs Thomas D.,Weiss Martina,Klaus Guido
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference5 articles.
1. Paris V, Docteur E.: Pharmaceutical pricing and reimbursement policies in Switzerland. OECD Health Working Papers 27, 1–60 (2007)
2. Paris V, Belloni A.: Value in pharmaceutical pricing. OECD Health Working Papers 63, 1–74 (2013)
3. Arzymanow B, Manning J.: Value-based pricing: the wrong medicine for the nation? Available from:
http://www.2020health.org/2020health/Publications/Publications-2013/-Value-based-pricing–the-wrong-medicine-for-the-nation-.html
(2014). Accessed 1 Sept 2014
4. Griffiths, E.A., et al.: Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold. Clinicoecon Outcomes Res 7, 463–476 (2015)
5. Nicod, E., Kanavos, P.: Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy 108(2–3), 167–177 (2012)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献